CARTITUDE-2 A Phase 2, Multicohort Open-Label study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy directed against BCMA in Subjects with Multiple Myeloma (68284528MMY2003) (Aktiv)
CC-92480-MM-002 A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (Aktiv)
Erstlinie
CARAMBA-1 A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells (Aktiv)
DREAMM9 (GSK 209664)) Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (Aktiv)
GMMG-HD-10/DSMM XX A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide and Dexamethasone with and without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma (Aktiv)
Paraproteinämische Keratopathie Inzidenz der paraproteinämischer Keratopathie bei Patienten mit monoklonaler Gammopathie unklarer Signifikanz, smoldering multiplem Myelom und multiplem Myelom (Aktiv)
TALMMY 1001-PT3,JNJ-64407564MMY1001 Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (Aktiv)
Zweitlinie oder später
64407564MMY1005 TRIMM-3 A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (Aktiv)
AGMT_MM1 Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma (Aktiv)
AMG 70120170122 The purpose of this First-in-Human Phase 1 study is to determine during the escalation part if AMG 701 given as weekly short term IV infusions is safe and tolerable followed by a dose expansion part to gain further efficacy and safety experience with AMG 701 in adult subjects with relapsed / refractory multiple myeloma (Aktiv)
ANV419-101 A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2) (Aktiv)
AlloRelapseMMStudy Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (Aktiv)
CC-220-MM-001 A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (Aktiv)
CC-4047 Study at several sites to evaluate pomalidomide taken with dexamethasone (low dose) in patients with Multiple Myeloma (MM) and impaired kidney function who did not respond to the previous treatment or whose disease has returned after the previous treatment (Aktiv)
DREAMM5 (GSK 208887) Platform Study of GSK2857916 as monotherapy and in combination with anti-cancer treatmentsin participants with RRMM (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
GMMG-DANTE Daratumumab in combination with Bortezomib and Dexamethason in subjects with Multiple Myeloma and severe renal impairment (Aktiv)
HDP-101-01 A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma. (Aktiv)
LYNX (54767414MMY2065) Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) (Aktiv)
MK7684A-004 Phase II Studie zu MK-7684A (Vibostolimab/Pembrolizumab) bei rezidivierenden/refraktären hämatologischen Krebserkrankungen (Aktiv)
MonumenTAL-3 A Phase 3 Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide (Tal-DP) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) or Talquetamab SC and Daratumumab SC (Tal-D), in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma (RLRMM) who Have Received at Least 2 Prior Lines of Therapy (MonumenTAL-3) (Aktiv)
PCYC-1138-CA Study of Ibrutinib in Combination with Pomalidomide and Dexamethasone (Aktiv)
Paraproteinämische Keratopathie Inzidenz der paraproteinämischer Keratopathie bei Patienten mit monoklonaler Gammopathie unklarer Signifikanz, smoldering multiplem Myelom und multiplem Myelom (Aktiv)
REGN5458 Phase I/II FIH Study of REGN5458 (anti-BCMA x andti-CD3 bispecific antibody) in patients with relapsed or refractory multiple myeloma (Aktiv)
TALMMY1001-PT3 A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma (Aktiv)
TRIMM-2, 64407564MMY1002 A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (Aktiv)